Vaxcyte, Inc. (NASDAQ:PCVX) COO Sells $229,020.00 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 3,000 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $76.34, for a total value of $229,020.00. Following the sale, the chief operating officer now owns 210,503 shares of the company’s stock, valued at $16,069,799.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Jim Wassil also recently made the following trade(s):

• On Monday, June 3rd, Jim Wassil sold 3,000 shares of Vaxcyte stock. The shares were sold at an average price of $71.99, for a total value of $215,970.00.

Vaxcyte Price Performance

Shares of Vaxcyte stock opened at $76.26 on Friday. Vaxcyte, Inc. has a fifty-two week low of $44.20 and a fifty-two week high of $82.04. The business has a 50-day moving average price of $70.84 and a 200 day moving average price of $68.34.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Wednesday, May 8th. The company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($1.13) by $0.28. On average, equities analysts forecast that Vaxcyte, Inc. will post -3.96 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

PCVX has been the topic of a number of recent analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $95.00 target price on shares of Vaxcyte in a research report on Friday, June 28th. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a research note on Thursday, June 20th.

Institutional Trading of Vaxcyte

A number of institutional investors and hedge funds have recently modified their holdings of PCVX. Parallel Advisors LLC lifted its position in shares of Vaxcyte by 155.3% in the 4th quarter. Parallel Advisors LLC now owns 411 shares of the company’s stock worth $26,000 after buying an additional 250 shares during the last quarter. Fidelis Capital Partners LLC bought a new position in Vaxcyte in the first quarter worth about $37,000. Covestor Ltd boosted its stake in Vaxcyte by 451.7% in the first quarter. Covestor Ltd now owns 1,153 shares of the company’s stock valued at $79,000 after acquiring an additional 944 shares during the period. Banque Cantonale Vaudoise grew its holdings in shares of Vaxcyte by 96.7% during the first quarter. Banque Cantonale Vaudoise now owns 1,184 shares of the company’s stock valued at $81,000 after purchasing an additional 582 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Vaxcyte during the 4th quarter worth approximately $208,000. 96.78% of the stock is owned by institutional investors and hedge funds.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.